ENOVNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31

Enovis CORP

Financials through Q2 FY2026, quarter ended Jul 3, 2026Last filing: 10-Q on Aug 6, 2026

$19.87+0.28 (+1.43%)

Close on Oct 19, 2026

Market cap: $1.14B
P/E (TTM): –
Dividend yield: –

Fundamental chart

Pick a measure to chart its full history

$2.25BFY2025, +8.8% a year since FY2011

Where these numbers come from

Parsed from the XBRL in Enovis's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-3 reverse split on May 10, 2022
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ENOV.

Revenue growth4.9% · median 5.0%

Gross margin61.1% · median 54.1%

Operating margin-45.1% · median 14.2%

Net margin-48.0% · median 10.1%

Company	Revenue	Growth
GMED	$3.14B	+19.7%
ENOV	$2.30B	+4.9%
MSA	$1.95B	+6.5%
IART	$1.65B	+1.6%
CNMD	$1.37B	+3.4%
SNN	–	–

Company

Next earnings (est.): Nov 5, 2026, before open
Exchange: NYSE
Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Fiscal year ends: December 31
Employees: 7,802
Held by institutions: 100.0%
Auditor: Ernst & Young LLP
SEC CIK: 1420800

Advertisement
300 × 250